Searchable abstracts of presentations at key conferences in endocrinology

ea0014oc6.7 | Cardiovascular endocrinology | ECE2007

Evaluation of tolvaptan, an oral vasopressin V2 receptor antagonist, in ‘asymptomatic’ hyponatremia: effects on sodium concentration and patient reported health outcomes

Gross Peter , Verbalis Joseph , Decaux Guy , Ouyang John , Hobart Mary , Orlandi Cesare , Czerwiec Frank

Background: Hyponatremia (Na+≤134 mmol/L), the most common electrolyte derangement, is caused by inappropriate vasopressin-mediated water resorption in the kidney. Treating symptomatic hyponatremia is difficult and risky; as difficult as maintaining normal sodium levels. We tested if tolvaptan, an oral vasopressin V2 receptor antagonist, improves hyponatremia and self-reported health outcomes.Methods: Two multicenter, randomized, double-blind, plac...